Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,047 | -259 | -1,077 | -2,923 | -7,226 |
| Depreciation Amortization | 3,727 | 3,084 | 2,377 | 2,923 | 3,122 |
| Accounts receivable | -248 | -507 | 142 | -83 | 1,250 |
| Other Working Capital | -37 | -2,269 | -1,733 | -571 | -1,665 |
| Other Operating Activity | 1,349 | 1,316 | 840 | 677 | 339 |
| Operating Cash Flow | $2,744 | $1,365 | $549 | $23 | $-4,180 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,065 | -1,579 | -728 | -840 | -1,623 |
| Purchase Sale Intangibles | N/A | N/A | -724 | N/A | N/A |
| Other Investing Activity | 0 | 0 | -724 | 0 | 0 |
| Investing Cash Flow | $-1,065 | $-1,579 | $-1,452 | $-840 | $-1,623 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 4,000 | 50 | 2,502 | 6,737 |
| Debt Repayment | -1,045 | -5,622 | -3,193 | -1,910 | -4,676 |
| Common Stock Issued | N/A | 1,375 | 1,773 | 2,692 | N/A |
| Dividend Paid | -16 | -16 | -16 | -16 | N/A |
| Other Financing Activity | -37 | -40 | -82 | -12 | -81 |
| Financing Cash Flow | $-1,098 | $-303 | $-1,468 | $3,256 | $1,980 |
| Exchange Rate Effect | 42 | -75 | 63 | 24 | -139 |
| Beginning Cash Position | 2,786 | 3,378 | 5,686 | 3,223 | 7,185 |
| End Cash Position | 3,409 | 2,786 | 3,378 | 5,686 | 3,223 |
| Net Cash Flow | $623 | $-592 | $-2,308 | $2,463 | $-3,962 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,744 | 1,365 | 549 | 23 | -4,180 |
| Capital Expenditure | -1,094 | -1,612 | -728 | -840 | -1,632 |
| Free Cash Flow | 1,650 | -247 | -179 | -817 | -5,812 |